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Abstract
HER2 overexpression/amplification is linked to trastuzumab response in breast/gastric cancers. One suggested
anti-EGFR resistance mechanism in colorectal cancer (CRC) is aberrant MEK–AKT pathway activation through
HER2 up-regulation. We assessed HER2-amplification/overexpression in stage II–III and IV CRC patients, assessing
relationships to KRAS/BRAF and outcome. Pathological material was obtained from 1914 patients in the QUASAR
stage II–III trial and 1342 patients in stage IV trials (FOCUS and PICCOLO). Tissue microarrays were created for
HER2 immunohistochemistry. HER2-amplification was assessed using FISH and copy number variation. KRAS/BRAF
mutation status was assessed by pyrosequencing. Progression-free survival (PFS) and overall survival (OS) data
were obtained for FOCUS/PICCOLO and recurrence and mortality for QUASAR; 29/1342 (2.2%) stage IV and
25/1914 (1.3%) stage II–III tumours showed HER2 protein overexpression. Of the HER2-overexpressing cases,
27/28 (96.4%) stage IV tumours and 20/24 (83.3%) stage II–III tumours demonstrated HER2 amplification by
FISH; 41/47 (87.2%) also showed copy number gains. HER2-overexpression was associated with KRAS/BRAF
wild-type (WT) status at all stages: in 5.2% WT versus 1.0% mutated tumours (p < 0.0001) in stage IV
and 2.1% versus 0.2% in stage II–III tumours (p = 0.01), respectively. HER2 was not associated with OS or
PFS. At stage II–III, there was no significant correlation between HER2 overexpression and 5FU/FA response. A
higher proportion of HER2-overexpressing cases experienced recurrence, but the difference was not significant.
HER2-amplification/overexpression is identifiable by immunohistochemistry, occurring infrequently in stage II–III
CRC, rising in stage IV and further in KRAS/BRAF WT tumours. The value of HER2-targeted therapy in patients
with HER2-amplified CRC must be tested in a clinical trial.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Colorectal cancer (CRC) is one of the leading causes of
cancer-related deaths, with 1.36 million new cases and
> 0.5 million deaths/year worldwide [1]. In stage IV
disease, cytotoxic agents such as fluorouracil, irinotecan
and oxaliplatin have led to improved survival. Further
improvements in outcomes have been seen with the
introduction of targeted therapies. These include the use
of monoclonal antibodies against the epidermal growth
factor receptor (EGFR) in patients with KRAS wild-type
(WT) tumours, although only a minority of patients
respond to this approach.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
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The HER family of tyrosine kinase receptors con-
sists of EGFR, HER2 (ErbB2), HER3 and HER4.
They are responsible for cell survival and proliferation
via signalling through the RAS–RAF–ERK and
PI3K–PTEN–AKT pathways [2]. HER2 has been
extensively studied in breast cancer, where gene ampli-
fication and overexpression of the protein is seen
in approximately 20% cases and is associated with
increased risk of recurrence and a poorer prognosis
[3–5]. Treatment of these patients with the anti-HER2
monoclonal antibody trastuzumab (Herceptin) has led
to improved survival in metastatic breast cancer [6].
HER2 overexpression has also been identified in other
cancers, such as gastric cancer [7]. FDA approval was
given for the use of trastuzumab in HER2-positive
metastatic gastric cancers following the results of the
ToGA trial, where median overall survival was 13.8
months in patients given trastuzumab with chemother-
apy, compared to 11.1 months in those patients given
chemotherapy alone [8]. Several studies have assessed
HER2 overexpression in CRC, with some reporting
membranous expression, varying in the range 2.1–11%
in [9–15], and others reporting cytoplasmic overexpres-
sion in the range 47.4–68.5% [12,16,17].
Topoisomerase IIα (TOP2A) alters the topology
of DNA during transcription by causing transient
double-strand breaks. The TOP2A gene is located telom-
eric of HER2 on chromosome 17q. It is co-amplified
with HER2 in 35% of HER2-positive breast cancers and
is associated with response to anthracyclines and other
agents, although evidence is mixed.
It is now accepted that in stage IV colorectal disease,
RAS mutations confer resistance to anti-EGFR therapy
and BRAF mutations are an indicator of poor prognosis;
however, even among patients with RAS WT tumours,
only a minority respond. One suggested mechanism
of drug resistance is aberrant signalling through the
up-regulation of other transmembrane receptors, such
as HER2. Here we compared the frequency of HER2
protein overexpression between 1914 stage II–III CRC
patients from the QUASAR clinical trial with 1342
patients from two CRC stage IV clinical trials, 888 from
FOCUS and 454 from PICCOLO. HER2 protein expres-
sion was assessed in relation to HER2 amplification,
as determined by FISH, KRAS and BRAF mutations,
recurrence rates (in QUASAR patients) and finally
to survival outcomes. Cases showing overexpression
were also assessed for whole-genome copy number
variation, HER2 amplification and associated TOP2A
amplification.
Materials and methods
Patients were recruited to the QUASAR (QUick And
Simple And Reliable) trial duringMay 1994–December
2003, and were randomly assigned to receive
5FU/folinic acid chemotherapy (n= 1622) or to
observation (n= 1617). Trial details are reported
elsewhere [18]. Tissue microarrays (TMAs) were con-
structed containing all cases with sufficient tumour
for three cores/array. Ethical approval was obtained
from both the West Midlands Multi-Centre Research
Ethics Committee (JR/MT/MREC/02/7/56a) and the
Northern and Yorkshire Research Ethics Committee
(08/H0903/62) for pathological substudies in QUASAR
(ISRCTN82375386).
The MRC CR08 FOCUS trial [Fluorouracil,
Oxaliplatin and CPT11 (irinotecan): Use and
Sequencing] ISRCTN79877428 recruited 2135 first-line
advanced colorectal cancer (aCRC) patients during
2000–2003, comparing strategies of sequential or com-
bination cytotoxic therapy, without targeted agents [19].
Prospective consent was obtained to retrieve stored
pathological material for research (MREC/99/3/1).
From the trial repository of 1700 samples, 888 samples
contained sufficient tumour material to provide three
tumour cores for TMA construction.
PICCOLO (Panitumumab, Irinotecan and
Cyclosporin in COLOrectal cancer therapy)
assessed second-line aCRC therapies, including the
EGFR-targeted agent panitumumab. It recruited 1198
patients during 2006–2010 [20,21]. Patient consent
was obtained to retrieve surplus stored pathological
material for research (REC/06/Q0906/38). TMAs were
made containing 582 patient samples, whose resection
samples contained sufficient tumour material to pro-
vide three tumour cores. Following TMA sectioning
and staining, 128 had missing cores or insufficient
tumour within cores, leaving 454 patients suitable for
assessment here.
HER2 immunohistochemistry
From each TMA, 5 μm sections were cut onto Superfrost
Plus slides and dried overnight at 37∘C. The slides were
dewaxed, then incubated in 4% hydrogen peroxide solu-
tion in methanol for 20 min, prior to antigen retrieval
in a pressure cooker for 2 min in unmasking solution
(Vector Laboratories, Burlingame, CA, USA). The
slides were incubated in a casein solution (Vector Lab-
oratories) for 10 min and then incubated for 1 h at room
temperature with the HER2 antibody (polyclonal rabbit
anti-human c-erbB-2 oncoprotein; cat no. A0485 from
Dako, Ely, UK) at a dilution of 1:250. The slides were
incubated for 30 min with secondary HRP-conjugated
anti-rabbit (Envision+ System HRP-labelled polymer,
Dako), then developed using 3,3′-diaminobenzidine
(DAB). The slides were counterstained with Mayer’s
haematoxylin and lithium carbonate, dehydrated and
mounted and then scanned using an Aperio scanner
(Leica Microsystems, Milton Keynes, UK) for visu-
alization and scoring. Tumour cores were deemed to
show strong overexpression of HER2 if the majority
of tumour cells displayed a ‘full basket weave’ pattern
of membrane staining in > 90% of cell membranes;
this level of expression is classified as 3+ using current
consensus-scoring guidelines [22]. To confirm the TMA
result and to assess the level of heterogeneity of HER2
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expression, whole sections from the tumours with over-
expression were also stained, according to the above
protocol.
HER2 fluorescence in situ hybridization (FISH)
FISH was carried out using the HER2 Kit (Kreat-
ech, Uckfield, UK) on 4 μm formalin-fixed,
paraffin-embedded (FFPE) tissue sections from the
tumours demonstrating HER2 overexpression by IHC,
according to the manufacturer’s instructions. Briefly,
a rhodamine-labelled HER2 probe was used to iden-
tify the number of target HER2 molecules, together
with a FITC-labelled control CEP17 probe, to identify
normal gene copy number. The ratio of HER2 signal
(red):CEP17 (green) was calculated in order to deter-
mine the presence or absence of HER2 amplification.
The criterion for gene amplification was an average
HER2:CEP17 ratio of ≥ 2 across at least 50 distinct,
non-overlapping tumour nuclei.
KRAS and BRAF pyrosequencing
For DNA extraction, the QIAamp DNAMicro kit (Qia-
gen, Manchester, UK) was used, employing the standard
manufacturer’s protocol. Primers for amplification and
pyrosequencing were designed using Pyrosequencing
Assay Design Software (Qiagen). KRAS codons 12–13
were amplified in one PCR reaction; KRAS codon 61
and BRAF codon 600 were amplified separately. Full
details of PCR reaction conditions have been published
elsewhere [23]. PCR products were pyrosequenced on a
PyroMark ID system (Qiagen), following the manufac-
turer’s protocols.
Copy number variation analysis
Forty-seven cases with overexpression/amplification of
HER2 (25 stage II–III and 22 stage IV) were run on
the OncoScan® FFPE Assay Kit (Affymetrix) to iden-
tify copy number alterations, according to the manufac-
turer’s instructions. Array fluorescence intensity (CEL)
files were generated automatically from DAT files using
Affymetrix® GeneChip® Command Console® (AGCC)
software v. 4.0. (Affymetrix). The CEL files were pro-
cessed by OncoScan® Console software to generate
OSCHP, which were loaded into Nexus Express for
OncoScan® (BioDiscovery, Hawthorne, CA, USA) for
analysis of clinically relevant copy number (CN) and
loss of heterozygosity (LOH) events. In parallel, somatic
mutations were visualised in a SomaticMutation Viewer
(Affymetrix) and cross-referenced with the CN data for
correlation with CN events.
Statistical analysis
Statistical analysis was carried out using STATA v. 12.
The proportion of tumours with strong HER2 overex-
pression was compared between KRAS/BRAF WT and
mutated tumours, using Fisher’s exact test. Cox’s pro-
portional hazards models were used to test for the effect
of HER2 strongly positive versus negative tumours
on recurrence rates, progression-free survival (PFS)
and overall survival (OS), separately for each trial.
Combined estimates were obtained by fixed effects
meta-analysis, testing for heterogeneity, in the two
stage IV trials.
Results
HER2 immunohistochemistry
We observed strong membranous staining for HER2
(Figure 1A) in 25 of 1914 (1.3%) stage II–III tumours
and 29 of 1342 (2.2%) stage IV tumours tested [18 of
888 (2.0%) in FOCUS; 11 of 454 (2.4%) in PICCOLO].
Weak membranous staining (Figure 1B) was observed
in a further 53 of 1342 (3.9%) cases [44 of 888 (4.9%)
in FOCUS, nine of 454 (2.0%) in PICCOLO tumours].
Corresponding whole-tumour sections for the 29 stage
IV tumours with strong membranous staining seen in
the TMA cores were stained, and showed homogeneous
overexpression across each tumour (Figure 1C).
HER2 FISH analysis
Whole sections of the 54 cases with strong membra-
nous staining by IHCwere then subjected toHER2 FISH
analysis; 24 of the 25 stage II–III tumours were success-
fully hybridized, with 20 of 24 (83.3%) showing HER2
amplification: 28 of 29 stage IV tumours were success-
fully hybridized, with 27 of 28 (96.4%) showing HER2
amplification (Figure 2); 10 of 53 stage IV tumours dis-
playing weak membranous IHC staining were randomly
selected for HER2 FISH analysis and none of these
tumours showed HER2 amplification.
HER2 copy number variation analysis by OncoScan
Forty-seven cases where strong membranous staining
of HER2 was observed were analysed for copy number
variation of HER2 and TOP2A using OncoScan: 41 of
47 (87.2%) showed amplification of HER2, two of 47
(4.3%) showed partial amplification of HER2 and the
remaining four showed no amplification of HER2; 17
of 47 (36.2%) showed co-amplification of HER2 and
TOP2A. HER2 amplification, as determined by FISH,
correlated strongly with amplification, as determined by
OncoScan analysis (Table 1).
HER2 and KRAS/BRAF mutation status
HER2 overexpression was strongly associated with
KRAS/BRAF WT status in all stages of disease. In the
QUASAR trial, HER2 overexpression was observed in
17 of 811 (2.1%) KRAS/BRAF WT tumours compared
with one of 421 (0.2%) tumours harbouring a KRAS
or BRAF mutation (p= 0.01). In the stage IV tumours,
strong HER2 staining was present in 24 of 466 (5.2%)
WT cases, compared with 5 of 525 (1.0%) of those
with a mutation (Fisher’s exact test, p < 0.0001). This
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Figure 1. (A) Core from a colorectal tumour, demonstrating strong
membranous overexpression of HER2; the cores were visually
inspected at a native scanning resolution of ×20. (B) Core from a
colorectal tumour, demonstrating weak membranous overexpres-
sion of HER2; the cores were visually inspected at a native scan-
ning resolution of ×20. (C) Whole-section staining was carried out
to determine the homogeneity of HER2 overexpression across the
tumour section; the location of each of the three cores that were
stained on the TMA (1, 2 and 3) is also shown; the cores were visu-
ally inspected at a native scanning resolution of ×20
Table 1. Correlation between amplification of HER2, as assessed
by FISH, and amplification, as determined by OncoScan (n= 47)
OncoScan
Amplification
Partial
amplification
No
amplification
FISH n (%) n (%) n (%)
Amplification 38 (80.9) n/a 2 (4.3)
No amplification 2 (4.3) 2 (4.3) 1 (2.1)
Assay failure 1 (2.1) n/a 1 (2.1)
difference was observed in each of the stage IV trial
datasets [FOCUS, 14 of 259 (5.4%) versus 4 of 284
(1.4%); PICCOLO, 10 of 207 (4.8%) versus 1 of 241
(0.4%)].
HER2 and recurrence rate, PFS and OS analysis
Clinical data was available in 1767 QUASAR cases.
There were no significant correlations between mem-
branous HER2 overexpression and either recurrence
or overall survival (OS) (Figure 3). There appears to
be a greater difference in recurrence between those
cases with HER2 overexpression and those showing no
overexpression, although this is not significant in the
group receiving chemotherapy. The numbers of recur-
rences in the treated group are similar to the number of
recurrences in the entire trial, and this is reflected in the
relative p values.
Associations of HER2 expression with OS and
progression-free survival (PFS) were first assessed in
the two stage IV trial datasets separately. In neither trial
was there a significant association. In FOCUS, com-
paring patients with HER2 strongly positive tumours
(n= 18) versus those with no visible membrane staining
(n= 826) gave a hazard ratio (HR) for OS of 0.81 [95%
confidence interval (CI) 0.50, 1.32; the HR for PFS
was 0.68, CI 0.42, 1.12]. Corresponding estimates from
the PICCOLO trial (n= 11 versus n= 434) were 0.98,
95% CI 0.54, 1.78 for OS and 0.80, 95% CI 0.44, 1.46
for PFS.
Combining the two datasets, there remains no evi-
dence for an effect on outcome [HR for OS, 0.87, 95%
CI 0.60, 1.27; p= 0.48; HR for PFS, 0.73, 95% CI
0.50, 1.07; p= 0.11], with no evidence for heterogene-
ity between the studies in either analysis (Figure 4).
Restricting these survival analyses to patients with
KRAS WT tumours, very similar results were obtained
[HR for OS from meta-analysis of the two trials, 0.99,
95% CI 0.65, 1.51; p= 0.95; HR for PFS, 0.83, 95% CI
0.54, 1.28; p= 0.40], with no evidence for heterogeneity
between studies.
Discussion
It has recently been demonstrated in aCRC that, in
addition to KRAS mutation status, mutations in other
proteins downstream of EGFR, including NRAS
and possibly also BRAF and PIK3CA, contribute to
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Figure 2. HER2 FISH analysis of two colorectal tumours, showing (A) amplification and (B) no amplification; red signals, HER2 probe; green
signals, CEP17 probe; amplification is described as a HER2:CEP17 ratio of ≥ 2
resistance to anti-EGFR therapies. Data from trials
such as PICCOLO [21] and PRIME [24] have provided
strong supporting evidence for this. However, even
tumours which are wild-type for all these genes have a
relatively high rate of drug-resistance.
HER2 has the ability to form heterodimers with EGFR
and HER3, and to activate the MAPK and AKT path-
ways. Overexpression of HER2 is therefore a potential
mechanism for circumventing EGFR blockade, mak-
ing it a potential biomarker of resistance to anti-EGFR
therapy and a potential selection criterion for novel
HER2- or HER3-targeted treatments. Bertotti et al [25]
provided early evidence using HER2-amplified tumour
xenografts, which demonstrated resistance to cetux-
imab. Accurate characterization of HER2 expression in
large patient populations is an important first step to its
development as a biomarker in aCRC.
In this study we assessed HER2 expression by
immunohistochemistry, identifying a subset of CRC
with strong overexpression of membranous HER2.
Overall, we observed this in just 25 of 1914 (1.3%)
stage II–III tumours and 29 of 1342 (2.2%) of stage
IV tumours, which, although a small proportion, still
represents a sizeable number of patients in this common
disease group. This low level of expression is almost
identical to that reported by Lee et al [14] when report-
ing on HER2 overexpression in 94 consecutive stage
IV CRCs. We found that 20 of 24 (83.3%) stage II–III
patients and 27 of 28 (96.4%) stage IV patients with
strong IHC staining also showed HER2 amplification
by FISH.
Several previous studies have assessed HER2 using
both IHC and FISH analyses, and also found that gene
amplification is a consistent finding in tumours with
strong (3+) membranous staining by IHC [9,11,15].
These studies also identified cases with moderate/weak
(2+) staining and equivocal amplification by FISH.
However, of the 1342 stage IV patients, we found no
cases falling into this intermediate staining category.
We identified 53 tumours with visible but weak (1+)
staining; 10 of these tumours, selected at random, under-
went HER2 FISH analysis, with none demonstrating
gene amplification. These results suggest that gene
amplification is associated with strong membranous
overexpression of HER2, and that IHC is a reliable
technique for assessing HER2 in CRC. It remains
unclear whether the HER2 status of these is represen-
tative of that of any corresponding metastases. Lee et al
[14] addressed this very question and determined that in
almost 15% of tumours, there was a lack of concordance
between the HER2 status in the primary tumour and
associated metastases. This may need to be taken into
account if future clinical trials are realised.
In order to confirm the amplification of the HER2
gene seen in the FISH analysis, 47 cases with strong
membranous overexpression of HER2 were analysed
using the Affymetrix OncoScan FFPE Assay Kit: 43
of 47 (91.4%) showed full or partial amplification of
HER2, suggesting that the OncoScan method is an
alternative way of assessing copy number variation;
only four of 47 cases (8.5%) showed no amplifica-
tion of HER2, including one case where analysis by
FISH failed and one case where FISH also showed no
amplification. We were also able to access OncoScan
data on 159 PICCOLO samples, which were negative
for HER2 protein expression. None of these tumours
demonstrated HER2 amplification. We feel this fur-
ther evidences the strong correlation between protein
expression and amplification, and is confirmation that
the negative tumours are not in fact ‘false negatives’.
These results suggest that HER2 expression is increased
in a small subset of intermediate and aCRC, and that
these cases may benefit from anti-HER2 therapies such
as trastuzumab and pertuzumab.
Seventeen of 47 cases (36.2%) showed
co-amplification of HER2 and TOP2A. These
results support existing reports of HER2/TOP2A
co-amplification in the range 21–42% [26–28].
In all disease stages, but particularly in stage IV, we
observed a significant association of HER2 overexpres-
sion with KRAS/BRAF WT tumours (p < 0.0001). This
is consistent with the hypothesis that HER2 amplifica-
tion may represent an alternative driver to MEK–AKT
pathway activation in tumours without an activating
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Figure 3. Kaplan–Meier estimates of recurrence and survival of patients in the QUASAR trial, with tumours showing overexpression or no
expression of HER2 protein
mutation of a downstream oncogene. One might pre-
dict that these HER2-amplified tumours would be resis-
tant to cetuximab or panitumumab therapy, and that
they may respond to targeted treatment against HER2,
or a combination of therapies targeting HER2, EGFR
and possibly also HER3. Such combinations have been
reported to inhibit growth in cetuximab-resistant cell
lines [25,29]. A recent clinical study reported HER2
amplification in seven of 170 (4%) KRAS WT patients
receiving cetuximab or panitumumab, and these patients
had inferior PFS and OS compared to those without
HER2 amplification; however, the small sample size lim-
its interpretation of this result [30].
Recently presented data on the HERACLES trial,
a phase II trial in HER2-amplified, KRAS exon 2 WT
mCRC patients of trastuzumab and lapatinib, achieved
its primary endpoint of an objective response (OR)
in > 30% of patients. This trial provided the first real
evidence that patients with HER2 amplification may
receive benefit from dual anti-HER2 treatments, and
certainly points to the incorporation of such therapies
earlier in the treatment of mCRC patients [31]. To
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Figure 4. Kaplan–Meier estimates of progression-free survival (PFS) and overall survival (OS) among patients in FOCUS (A and C,
respectively) and PICCOLO (B and D, respectively), with tumours showing overexpression or no expression of HER2 protein
ensure that the correct patients were enrolled into the
HERACLES trial, work was carried out by Valtorta
et al [32] to develop criteria to accurately define HER2
positivity in colorectal tumours. According to these
criteria, HER2 positivity was defined as the presence of
intense, homogeneous membranous staining in at least
50% of tumour cells, and these tumours also showed
HER2 amplification by FISH. The study also reported
a rate of HER2 amplification in KRAS WT tumours of
just over 5%, consistent with our findings of 5.2%. This
provides additional evidence that our negative tumours
are indeed true negatives.
In the QUASAR trial, we did not find a significant
correlation between HER2 expression and recurrence or
survival. Furthermore, we did not find an association
between HER2 expression and PFS or OS in the stage
IV trials. Due to the rarity of HER2 overexpression,
the power to detect a modest effect on outcome is low,
but we can exclude a strong effect. This agrees with
two previous studies, which failed to detect a prognostic
biomarker effect for HER2 [10,13].
One area we have not investigated in this study is the
presence of activating mutations in the HER2 gene. A
recent functional analysis by Kloth et al [33] revealed
a differential response to HER2-targeted therapies in
HER2-mutant MSI CRC cell lines. A similar response
was also shown by Kavuri et al [34], where treatment of
HER2-mut CRC cell-lines with a single HER2-targeted
agent produced delayed tumour growth and treatment
with dual agents (anti-HER2 therapy plus a tyrosine
kinase inhibitor) produced tumour regression. Bertotti
et al [35] recently carried out exome sequence and copy
number analyses of both patient-derived xenografts and
patient tumours, to investigate the effects of mutations
in ERBB2, EGFR, FGFR1, PDGFRA and MAP2K1
in relation to resistance to anti-EGFR therapies. Point
mutations were detected in both the kinase domain and
the ectodomain of HER2, and these correlated with
cetuximab resistance. This provides early evidence of
a role for somatic mutations in the activation of HER2
signalling, resulting in anti-EGFR therapy resistance.
With the advent of next-generation sequencing, this is
one area which ought to be investigated further, with the
aim of defining a HER2-mutant cohort who may gain
benefit from HER2-targeted therapies.
In conclusion, we have identified, within these large
clinical trial cohorts, a small subset of patients with
tumours overexpressing membranous HER2 and having
amplification of the HER2 gene confirmed by FISH
and microarray studies. HER2 overexpression is not a
prognostic biomarker; however, it is strongly associated
with RAS/RAF WT status and TOP2A amplification.
This raises the hypothesis that HER2 amplification is an
alternative driver of MEK–AKT pathway activation in
CRC. We propose that HER2 should now be assessed
as a putative biomarker of resistance to anti-EGFR
therapy in RAS/RAF WT patients, as a potential pre-
dictive biomarker for HER2-targeted therapy and, if
further studies confirm that TOP2A amplification is
associated with anthracycline sensitivity, it might be
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worth screening for HER2 overexpression to triage for
its presence in this disease.
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